Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Phase 2a Study to Assess the Safety and Efficacy of Cilnidipine (10 mg and 20 mg) Alone and in Combination with 5 mg Tadalafil, in Participants with Diagnosis of Secondary Raynaud's Disease

X
Trial Profile

A Randomized, Placebo-controlled Phase 2a Study to Assess the Safety and Efficacy of Cilnidipine (10 mg and 20 mg) Alone and in Combination with 5 mg Tadalafil, in Participants with Diagnosis of Secondary Raynaud's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilnidipine (Primary) ; Tadalafil (Primary)
  • Indications Raynaud's disease
  • Focus Therapeutic Use
  • Acronyms RECONNOITER-1
  • Sponsors AISA Pharma Australia
  • Most Recent Events

    • 21 Jun 2023 According to an Aisa Pharma Media Release, initial positive safety and efficacy data from this trial presented at EULAR 2023
    • 21 Jun 2023 Initial positive safety and efficacy data from this trial presented in the Aisa Pharma Media Release
    • 21 Jun 2023 According to an Aisa Pharma Media Release, the company announced initiation of Part 2 of this RECONNOITER Phase 2 study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top